OPM's Scientific Advisory Board
Oxford Performance Materials (OPM) is pleased to announce that the company has formed a Scientific Advisory Board (SAB) whose distinguished members represent a very high level of expertise in all of the technical and medical segments that have a strong relationship to OPM’s product lines and future developments. The SAB members will assist our management team in a number of ways, including the assessment of technology options, development of new technologies, and utilization of OPM’s breakthrough innovations. The contributions of the SAB team will play an important role in OPM’s mission to become a leading manufacturer of advanced materials and components.
Scientific Advisory Board members
Timothy Ganey, Ph.D.
Dr. Timothy Ganey is Director of Research for the Atlanta Medical Center, and has co-appointments with the Atlanta VA, University of South Florida, and the Translational and Regenerative Medicine Institute at the University of Leipzig in Germany. He has been instrumental in several technology development initiatives, among them the use of cell-based therapeutics, energy field transduction, instructive biomaterials, and tissue specific matrices for regenerative medicine. He is currently (2011-2012) Guest Professor at the Fraunhofer Institute in Leipzig to further develop electrospun nanomaterials. Timothy Ganey received a BS/BA degree from the University of Illinois with a major in Chemistry and Biology, did post-graduate work in Electron Microscopy, and completed a Ph.D. at the University of South Florida. His work focuses on shifting the paradigm of clinical medicine to regenerative treatment through engineering and scientifically-grounded developmental initiatives. Simply put, outcome in regenerative medicine only emerges as a therapeutic option when scientific discovery translates to clinical practice.
Prof. Dr. med H.J. Meisel
Prof. Hans-Jörg Meisel has over 20 years of experience in Neurosurgery. In 1998 he was appointed to the Clinic in Bergmannstrost Halle/Saale as Director of the Clinic for Neurosurgery. Every year their team of 10 surgeons carries out a minimum of 1800 surgeries in the area of cerebral and spinal disease. He has studied the clinical implantation of fusion devices for stabilization of the cervical and lumbar spine, the promotion of bone fusion between vertebrae following the treatment of spine disorders with biological implants, autologous disc chondrocyte transplantation (phase II and III studies), and mesenchymal stem cells as means of obtaining functional restoration for disc collapse. Professor Meisel is CEO of the European Network for Regenerative Medicine EEIG REGENERATE which integrates ten countries of the European Union that carry out research in the area of Regenerative Medicine. He also heads a research group of five PhDs at the Translational Centre for Regenerative Medicine at the University of Leipzig, supported by the Federal ministry of Education and Research (BMBF) as part of the Excellence Initiative of the German Federal Republic. In August 2007 Hans Jörg Meisel was appointed as an Associate Professor at the Department of Orthopaedic Surgery at the "Vrije Universiteit" Medical Center of Amsterdam (VUMC). Since September 2008 Hans Jörg Meisel has been the appointed Director of the Center of Neurosciences of the BG-Clinic Bergmannstrost Halle.
Carl McMillin, Ph.D.
Dr. Carl McMillin is deeply involved in many aspects of the biomedical engineering community, with experience both as an educator and an innovator. At the University of Akron, he helped found the Biomedical Engineering Department, teaching courses on biomaterials and artificial organs, and was Director of the Cardiovascular Laboratory for six years. As a contract manager at Monsanto Research Corporation, he directed the acquisition and conduct of a wide range of government research contracts and worked to develop accelerated fatigue tests for rubbers of potential use in artificial heart manufacture for the NIH. Dr. McMillin spent eight years as Senior Scientist at AcroMed, helping to develop new devices and bring them to market. He holds a BS in Mechanical Engineering from General Motors Institute of Technology, and has a MS and Ph.D. in Macromolecular Science with a minor in Operations Research from Case Western Reserve University (CWRU) with a doctoral thesis on the structure and function of blood-clotting proteins. He completed a NIH/NHLBI post-doctoral fellowship on blood platelet/surface interactions. He has been a member of the Adjunct Staff of the Cleveland Clinic for most years since 1984 and currently serves on the Editorial Advisory Board of Medical Plastics and Biomaterials, Canon Communications, Inc, and on the commercialization and advisory boards of the Edison Biotechnology Center.